

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		SECURITY INTEREST	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Scientific Testing Laboratories, Inc.		03/01/2010	CORPORATION: VIRGINIA
RECEIVING PARTY DATA			
Name:	General Electric Capital Corporation, as Agent		
Street Address:	2 Bethesda Metro Center		
Internal Address:	Suite 600		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1234063	SCIENTIFIC TESTING LABORATORIES, INC.	
CORRESPONDENCE DATA			
Fax Number:	(212)230-7740		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	212-318-6556		
Email:	kathleenmangual@paulhastings.com		
Correspondent Name:	Kathleen Mangual		
Address Line 1:	c/o Paul Hastings, LLP		
Address Line 2:	75 East 55th Street		
Address Line 4:	New York, NEW YORK 10022		
ATTORNEY DOCKET NUMBER:	56704.00101 KROLL 2ND LIE		
NAME OF SUBMITTER:	Kathleen Mangual		
Signature:	/s/ Kathleen Mangual		

CH \$40.00 1234063

900156894

**TRADEMARK
 REEL: 004166 FRAME: 0001**

Date:

03/11/2010

Total Attachments: 162

source=Kroll Second Lien#page1.tif
source=Kroll Second Lien#page2.tif
source=Kroll Second Lien#page3.tif
source=Kroll Second Lien#page4.tif
source=Kroll Second Lien#page5.tif
source=Kroll Second Lien#page6.tif
source=Kroll Second Lien#page7.tif
source=Kroll Second Lien#page8.tif
source=Kroll Second Lien#page9.tif
source=Kroll Second Lien#page10.tif
source=Kroll Second Lien#page11.tif
source=Kroll Second Lien#page12.tif
source=Kroll Second Lien#page13.tif
source=Kroll Second Lien#page14.tif
source=Kroll Second Lien#page15.tif
source=Kroll Second Lien#page16.tif
source=Kroll Second Lien#page17.tif
source=Kroll Second Lien#page18.tif
source=Kroll Second Lien#page19.tif
source=Kroll Second Lien#page20.tif
source=Kroll Second Lien#page21.tif
source=Kroll Second Lien#page22.tif
source=Kroll Second Lien#page23.tif
source=Kroll Second Lien#page24.tif
source=Kroll Second Lien#page25.tif
source=Kroll Second Lien#page26.tif
source=Kroll Second Lien#page27.tif
source=Kroll Second Lien#page28.tif
source=Kroll Second Lien#page29.tif
source=Kroll Second Lien#page30.tif
source=Kroll Second Lien#page31.tif
source=Kroll Second Lien#page32.tif
source=Kroll Second Lien#page33.tif
source=Kroll Second Lien#page34.tif
source=Kroll Second Lien#page35.tif
source=Kroll Second Lien#page36.tif
source=Kroll Second Lien#page37.tif
source=Kroll Second Lien#page38.tif
source=Kroll Second Lien#page39.tif
source=Kroll Second Lien#page40.tif
source=Kroll Second Lien#page41.tif
source=Kroll Second Lien#page42.tif
source=Kroll Second Lien#page43.tif
source=Kroll Second Lien#page44.tif
source=Kroll Second Lien#page45.tif
source=Kroll Second Lien#page46.tif
source=Kroll Second Lien#page47.tif
source=Kroll Second Lien#page48.tif
source=Kroll Second Lien#page49.tif
source=Kroll Second Lien#page50.tif
source=Kroll Second Lien#page51.tif
source=Kroll Second Lien#page52.tif

source=Kroll Second Lien#page53.tif
source=Kroll Second Lien#page54.tif
source=Kroll Second Lien#page55.tif
source=Kroll Second Lien#page56.tif
source=Kroll Second Lien#page57.tif
source=Kroll Second Lien#page58.tif
source=Kroll Second Lien#page59.tif
source=Kroll Second Lien#page60.tif
source=Kroll Second Lien#page61.tif
source=Kroll Second Lien#page62.tif
source=Kroll Second Lien#page63.tif
source=Kroll Second Lien#page64.tif
source=Kroll Second Lien#page65.tif
source=Kroll Second Lien#page66.tif
source=Kroll Second Lien#page67.tif
source=Kroll Second Lien#page68.tif
source=Kroll Second Lien#page69.tif
source=Kroll Second Lien#page70.tif
source=Kroll Second Lien#page71.tif
source=Kroll Second Lien#page72.tif
source=Kroll Second Lien#page73.tif
source=Kroll Second Lien#page74.tif
source=Kroll Second Lien#page75.tif
source=Kroll Second Lien#page76.tif
source=Kroll Second Lien#page77.tif
source=Kroll Second Lien#page78.tif
source=Kroll Second Lien#page79.tif
source=Kroll Second Lien#page80.tif
source=Kroll Second Lien#page81.tif
source=Kroll Second Lien#page82.tif
source=Kroll Second Lien#page83.tif
source=Kroll Second Lien#page84.tif
source=Kroll Second Lien#page85.tif
source=Kroll Second Lien#page86.tif
source=Kroll Second Lien#page87.tif
source=Kroll Second Lien#page88.tif
source=Kroll Second Lien#page89.tif
source=Kroll Second Lien#page90.tif
source=Kroll Second Lien#page91.tif
source=Kroll Second Lien#page92.tif
source=Kroll Second Lien#page93.tif
source=Kroll Second Lien#page94.tif
source=Kroll Second Lien#page95.tif
source=Kroll Second Lien#page96.tif
source=Kroll Second Lien#page97.tif
source=Kroll Second Lien#page98.tif
source=Kroll Second Lien#page99.tif
source=Kroll Second Lien#page100.tif
source=Kroll Second Lien#page101.tif
source=Kroll Second Lien#page102.tif
source=Kroll Second Lien#page103.tif
source=Kroll Second Lien#page104.tif
source=Kroll Second Lien#page105.tif
source=Kroll Second Lien#page106.tif
source=Kroll Second Lien#page107.tif

source=Kroll Second Lien#page108.tif
source=Kroll Second Lien#page109.tif
source=Kroll Second Lien#page110.tif
source=Kroll Second Lien#page111.tif
source=Kroll Second Lien#page112.tif
source=Kroll Second Lien#page113.tif
source=Kroll Second Lien#page114.tif
source=Kroll Second Lien#page115.tif
source=Kroll Second Lien#page116.tif
source=Kroll Second Lien#page117.tif
source=Kroll Second Lien#page118.tif
source=Kroll Second Lien#page119.tif
source=Kroll Second Lien#page120.tif
source=Kroll Second Lien#page121.tif
source=Kroll Second Lien#page122.tif
source=Kroll Second Lien#page123.tif
source=Kroll Second Lien#page124.tif
source=Kroll Second Lien#page125.tif
source=Kroll Second Lien#page126.tif
source=Kroll Second Lien#page127.tif
source=Kroll Second Lien#page128.tif
source=Kroll Second Lien#page129.tif
source=Kroll Second Lien#page130.tif
source=Kroll Second Lien#page131.tif
source=Kroll Second Lien#page132.tif
source=Kroll Second Lien#page133.tif
source=Kroll Second Lien#page134.tif
source=Kroll Second Lien#page135.tif
source=Kroll Second Lien#page136.tif
source=Kroll Second Lien#page137.tif
source=Kroll Second Lien#page138.tif
source=Kroll Second Lien#page139.tif
source=Kroll Second Lien#page140.tif
source=Kroll Second Lien#page141.tif
source=Kroll Second Lien#page142.tif
source=Kroll Second Lien#page143.tif
source=Kroll Second Lien#page144.tif
source=Kroll Second Lien#page145.tif
source=Kroll Second Lien#page146.tif
source=Kroll Second Lien#page147.tif
source=Kroll Second Lien#page148.tif
source=Kroll Second Lien#page149.tif
source=Kroll Second Lien#page150.tif
source=Kroll Second Lien#page151.tif
source=Kroll Second Lien#page152.tif
source=Kroll Second Lien#page153.tif
source=Kroll Second Lien#page154.tif
source=Kroll Second Lien#page155.tif
source=Kroll Second Lien#page156.tif
source=Kroll Second Lien#page157.tif
source=Kroll Second Lien#page158.tif
source=Kroll Second Lien#page159.tif
source=Kroll Second Lien#page160.tif
source=Kroll Second Lien#page161.tif
source=Kroll Second Lien#page162.tif

TRADEMARK

REEL: 004166 FRAME: 0004

SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 26, 2007, is made by each of the entities listed on the signature pages hereof (each a "Grantor" and, collectively, the "Grantors"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative agent and collateral agent (in such capacity, together with its successors and permitted assigns, the "Administrative Agent") for the Lenders and the L/C Issuers (as defined in the Second Lien Credit Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Second Lien Credit Agreement, dated as of June 26, 2007 (as amended, restated, supplemented or otherwise modified from time to time, the "Second Lien Credit Agreement"), among the Borrower, Holdings and the Lenders from time to time party thereto and Administrative Agent and the Lenders have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a Second Lien Guaranty and Security Agreement of dated as of June 26, 2007 herewith in favor of the Administrative Agent (the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Second Lien Credit Agreement) of the other Loan Parties; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Administrative Agent to enter into the Second Lien Credit Agreement and to induce the Lenders to make or continue to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations on the terms set forth in the Loan Documents, hereby mortgages, pledges and hypothecates to the Administrative Agent, for the benefit of the Secured Parties, and grants to the Administrative Agent, for the benefit of the Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the "Intellectual Property Collateral"):

(a) Copyrights.

(i) all of its Copyrights and registrations and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Copyright, including, without limitation, those referred to on Schedule 1A hereto;

(ii) all renewals, reversions and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(b) Patents.

(i) all of its registered Patents and applications for registration therefor and all registered IP Licenses and applications thereof providing for the grant to such Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1B hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(c) Trademarks.

(i) all of its Trademarks and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1C hereto;

(ii) all renewals and extensions of the foregoing;

(iii) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(iv) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with such Grantor's Intellectual Property Collateral and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

IM US HOLDINGS, LLC
INVERNESS MEDICAL INNOVATIONS, INC.
ADVANTAGE DIAGNOSTICS CORPORATION
APPLIED BIOTECH, INC.
BINAX, INC.
FIRST CHECK DIAGNOSTICS CORP.
FOREFRONT DIAGNOSTICS, INC.
INCA ACQUISITION, INC.
INNOVATIVE MOBILITY, LLC
INSTANT TECHNOLOGIES, INC.
INVERNESS MEDICAL – BIOSTAR, INC.
INVERNESS MEDICAL INTERNATIONAL
HOLDING CORP.
INVERNESS MEDICAL INTERNATIONAL
HOLDING CORP. II
INNOVATIONS RESEARCH, LLC
INVERNESS MEDICAL, LLC
ISCHEMIA TECHNOLOGIES, INC.
IVC INDUSTRIES, INC.
INNOVACON, INC.
OSTEX INTERNATIONAL, INC.
QUALITY ASSURED SERVICES, INC.
SELFCARE TECHNOLOGY, INC.
SPDH, INC.
UNIPATH ONLINE, INC.
WAMPOLE LABORATORIES, LLC, as Grantors

Approved
As To Form


Legal Department

By: 
Name: David Teitel

Title: President, Chief Financial Officer & Treasurer,
Vice President, Finance, Vice President, Vice
President, Finance, Vice President, Finance,
Vice President, Treasurer, Chief Financial
Officer, Vice President, Finance, Vice President,
Finance, President, President, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
Finance, Vice President, Finance, Vice
President, Finance, Chief Financial Officer, Vice
President, Finance, President, Vice
President, Vice President

[SIGNATURE PAGE TO SECOND LIEN IP SECURITY AGREEMENT]

LEGAL_US_E # 75504436

TRADEMARK
REEL: 004166 FRAME: 0008

ACCEPTED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: Andrew Moore

Name:

Andrew D Moore

Title:

Duly Authorized Signatory

[SIGNATURE PAGE TO SECOND LIEN IP SECURITY AGREEMENT]

LEGAL_US_E # 75504436

TRADEMARK
REEL: 004166 FRAME: 0009

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED COPYRIGHTS

None.

B. COPYRIGHT APPLICATIONS

None.

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED PATENTS

[Include Owner, Registration Number and Date]

B. PATENT APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

BNX0004	SE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	US	18/SEP/1999	09/397110	30/NOV/2004	6624997	Binax, Inc.	18/SEP/2019
BNX0005	US	19/NOV/1999	09/443211	27/APR/2004	6727073	Binax, Inc.	19/NOV/2019
BNX0006	AU	11/DEC/2000	24293/01	16/MAR/2006	783777	Binax, Inc.	11/DEC/2020
BNX0005	CA	11/DEC/2000	2393628			Binax, Inc.	11/DEC/2020
BNX0006	EP	11/DEC/2000	00988037.8			Binax, Inc.	11/DEC/2020
BNX0006	US	10/DEC/1999	09/458998			Binax, Inc.	10/DEC/2019
BNX0007	AU	01/MAR/2001	2001241867	01/SEP/2005	2001241867	Binax, Inc.	01/MAR/2021
BNX0007	CA	19/AUG/2002	2427693			Binax, Inc.	19/AUG/2022
BNX0007	EP	01/MAR/2001	01813177.0			Binax, Inc.	01/MAR/2021
BNX0007	JP	01/MAR/2001	2001-563134			Binax, Inc.	01/MAR/2021
BNX0007	US	01/MAR/2000	09/518165			Binax, Inc.	01/MAR/2020
BNX0008	US	15/JAN/2002	10/044920	28/MAR/2006	7016849	Binax, Inc.	15/JAN/2022
BNX0008	US	07/DEC/2005	11/295486			Binax, Inc.	27/FEB/2022
BNX0009	US	27/FEB/2002	10/063476			Binax, Inc.	27/FEB/2022
BNX0011	AU	24/FEB/2004	2004216189			Binax, Inc.	24/FEB/2024
BNX0011	CA	24/FEB/2004	2516546			Binax, Inc.	24/FEB/2024
BNX0011	CN	24/FEB/2004	200480006045.4			Binax, Inc.	24/FEB/2024
BNX0011	EP	24/FEB/2004	04714110.6			Binax, Inc.	24/FEB/2024
BNX0011	HK	24/FEB/2004	06105886.0			Binax, Inc.	24/FEB/2024
BNX0011	JP	24/APR/2004	10/784155			Binax, Inc.	24/FEB/2024
BNX0011	US	29/JUL/2005	200510084798.5			Binax, Inc.	29/JUL/2025
BNX0012	CN	16/NOV/2004	10/989050			Binax, Inc.	16/SEP/2019
BNX0012	US	23/MAY/2007	11/740738			Binax, Inc.	16/SEP/2019
BNX0015	US	08/DEC/2006	60/873665			Binax, Inc.	08/DEC/2007
BNX0016	US	08/AUG/2006	60/836200			Binax, Inc.	08/DEC/2007
BNX0018	CN	01/MAR/2005	200580013856.1			Binax, Inc.	08/AUG/2007
BNX0018	EP	01/MAR/2005	05724003.8			Binax, Inc.	01/MAR/2025
BNX0019	AU	26/NOV/2003	2003295951			Binax, Inc.	01/MAR/2025
BNX0019	CA	26/NOV/2003	2541135			Binax, Inc.	26/NOV/2023
BNX0019	CN	26/NOV/2003	200380110715.2			Binax, Inc.	26/NOV/2023
BNX0019	EP	26/NOV/2003	03787168.2			Binax, Inc.	26/NOV/2023
BNX0019	IN	26/NOV/2003	1766/KOLNFI/2006			Binax, Inc.	26/NOV/2023
BNX0019	JP	26/NOV/2003	2005-512637			Binax, Inc.	26/NOV/2023
BNX0019	NZ	26/NOV/2003	PCT/US2003/037787			Binax, Inc.	26/NOV/2023
BNX0019	US	16/NOV/2004	10/969973			Binax, Inc.	26/NOV/2023
BNX0020	CN	17/FEB/2005	200580009058.1			Binax, Inc.	26/NOV/2023
BNX0020	EP	17/FEB/2005	05807655.5			Binax, Inc.	26/NOV/2023
BNX0020	US	17/FEB/2005	11/062211			Binax, Inc.	26/NOV/2023
BNX0020	US	17/FEB/2005	PCT/US2005/005036			Binax, Inc.	26/NOV/2023
BNX0021	CN	17/FEB/2005	200580010581.6			Binax, Inc.	26/NOV/2023
BNX0021	EP	17/FEB/2005	05723144.1			Binax, Inc.	17/FEB/2025
BNX0021	IN	17/FEB/2005	PCT/US2005/004896			Binax, Inc.	17/FEB/2025
BNX0021	JP	17/FEB/2005	2006-554175			Binax, Inc.	17/FEB/2025
BNX0021	US	17/FEB/2005	11/060113			Binax, Inc.	17/FEB/2025
BNX0021	US	17/FEB/2005	11/060113			Binax, Inc.	17/FEB/2025
BNX0022	CN	06/OCT/2005	PCT/US2005/035967			Binax, Inc.	06/OCT/2025

BNX0022	EP	06/OCT/2005	PCT/US2005/035967	19/JAN/2006	763246	Blnax, Inc.	06/OCT/2025
BNX0022	IN	06/OCT/2005	PCT/US2005/035967	29/NOV/2006	00817003.7	Blnax, Inc.	06/OCT/2025
BNX0022	JP	06/OCT/2005	PCT/US2005/035967	13/APR/2005	60019458.2	Blnax, Inc.	06/OCT/2024
BNX0022	US	06/OCT/2005	11244996	13/APR/2005	1242876	Blnax, Inc.	08/DEC/2007
BNX0025	US	08/DEC/2006	60878750	13/APR/2005	1242576	Blnax, Inc.	05/JAN/2008
BNX0027	US	05/JAN/2007	60878750	13/APR/2005	1242876	Blnax, Inc.	20/OCT/2007
BNX0028	US	20/OCT/2006	60863264	24/NOV/2006	3884652	Blnax, Inc.	17/JAN/2008
BNX0028	US	17/JAN/2007	60860791	11/JUL/2006	NI-257953	Blnax, Inc.	10/APR/2008
BNX0029	US	10/APR/2007	60910904	17/JUN/2006	6579688	Blnax, Inc.	02/SEP/2023
BNX0033	US	02/SEP/2003	10655321	21/NOV/2001	NI-144889	Blnax, Inc.	22/MAY/2021
BNX0023	US	22/MAY/2001	2409151	18/SEP/1986	6912252.5	Forefront Diagnostics, Inc.	29/MAR/2022
ABI0006	CA	29/MAR/2002	2443077	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
ABI0007	CA	07/DEC/2000	2076001	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	AU	07/DEC/2000	00817003.7	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	CN	07/DEC/2000	00817003.7	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	DE	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	DE	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	EP	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	EP	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	FR	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	FR	07/DEC/2000	00984071.1	18/SEP/1986	0539363	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	GB	07/DEC/2000	2001-545519	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	GB	07/DEC/2000	2002-7007547	26/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	JP	07/MAR/2001	89126736	28/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	KR	07/MAR/2001	89126736	28/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	TW	14/DEC/2000	09737636	28/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	TW	14/DEC/2000	09737636	28/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	US	15/APR/2002	10123750	20/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0001	US	15/APR/2002	10123750	20/FEB/1997	0493484	Forefront Diagnostics, Inc.	07/DEC/2020
BST0002	TW	09/JAN/2001	89115794	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	DE	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	DE	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	EP	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	EP	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	ES	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	FR	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	FR	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	GB	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	GB	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	HK	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	HK	20/MAR/1991	91910056.0	24/APR/1998	1000736	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	IT	20/MAR/1991	50934491	25/MAY/2001	3193373	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	IT	20/MAR/1991	50934491	25/MAY/2001	3193373	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	JP	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0004	JP	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	DE	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	DE	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	EP	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	EP	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	FR	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	FR	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	GB	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	GB	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	HK	18/SEP/1990	97102316.7	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	HK	18/SEP/1990	97102316.7	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	IT	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	IT	18/SEP/1990	90914615.1	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	18/SEP/1990	2-513769	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	18/SEP/1990	2-513769	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	18/SEP/1990	10-5911	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	18/SEP/1990	10-5911	26/FEB/1997	69030004.2	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	31/JUL/1992	078923304	09/JUL/1999	2951300	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	JP	31/JUL/1992	078923304	09/JUL/1999	2951300	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	US	28/MAR/1995	08/412600	21/NOV/1995	5468606	Forefront Diagnostics, Inc.	07/DEC/2020
BST0005	US	28/MAR/1995	08/412600	21/NOV/1995	5468606	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	DE	11/FEB/1992	92906299.0	17/JUN/1997	5638671	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	DE	11/FEB/1992	92906299.0	17/JUN/1997	5638671	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	EP	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	EP	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	ES	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	ES	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	FR	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	FR	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	GB	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	GB	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	HK	11/FEB/1992	98100895.9	21/MAR/2003	1001889	Forefront Diagnostics, Inc.	07/DEC/2020
BST0006	HK	11/FEB/1992	98100895.9	21/MAR/2003	1001889	Forefront Diagnostics, Inc.	07/DEC/2020

BST0006	IT	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0006	JP	11/FEB/1992	505739/92	28/JUL/2008	3833507	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0006	JP	16/SEP/2003	2003-323351			Inverness Medical - Biostar Inc.	11/FEB/2012
BST0006	US	10/JUN/1993	08076347	27/AUG/1996	5550053	Inverness Medical - Biostar Inc.	27/AUG/2013
BST0007	DE	11/FEB/1992	92907304.7	26/NOV/1998	89227655.6	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0007	EP	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0007	ES	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0007	FR	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0007	GB	11/FEB/1992	92907304.7	24/MAR/2000	1001890	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0007	HK	11/FEB/1992	98100899.5	26/NOV/1998	0525178	Inverness Medical - Biostar Inc.	11/FEB/2012
BST0008	IT	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	BE	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	DE	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	EP	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	ES	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	FR	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	GB	01/OCT/1991	91308988.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	HK	01/OCT/1991	97102309.6	24/APR/1998	1000771	Inverness Medical - Biostar Inc.	01/OCT/2011
BST0008	JP	24/SEP/1992	198609/98	08/SEP/2000	3107787	Inverness Medical - Biostar Inc.	24/SEP/2012
BST0008	JP	24/SEP/1992	254562/92	02/OCT/1998	2834950	Inverness Medical - Biostar Inc.	24/SEP/2012
BST0009	US	10/JUN/1993	08076320	09/JAN/1996	5482830	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0009	US	17/APR/1995	06/403565	21/SEP/1999	5955377	Inverness Medical - Biostar Inc.	21/SEP/2016
BST0009	US	31/MAY/1995	08/458640	13/MAY/1997	5629214	Inverness Medical - Biostar Inc.	31/MAY/2015
BST0010	US	31/MAY/1995	08/455652	09/FEB/1999	5869272	Inverness Medical - Biostar Inc.	09/FEB/2016
BST0010	US	10/JUN/1993	08076719	23/MAY/1995	5418138	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	EP	10/JUN/1993	01108521.4	23/MAY/2007	1126278	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	EP	10/JUN/1993	83815341.7	14/DEC/2005	0727038	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	EP	10/JUN/1993	05027236.8	14/DEC/2005	0727038	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	GB	10/JUN/1993	93915341.7	23/MAY/2007	1126278	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	GB	10/JUN/1993	01108521.4	13/OCT/2006	1003304	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	HK	10/JUN/1993	98102353.0			Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	10/JUN/1993	2001-236593	28/APR/2005	3673469	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	10/JUN/1993	2001-236166	01/AUG/2003	3456984	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	10/JUN/1993	2001-236411	26/DEC/2003	3506703	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	10/JUN/1993	1994-505280	31/MAR/2006	3767143	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	10/JUN/1993	276389/2004	23/APR/2004	3547723	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	03/AUG/2001	2001-236198	26/DEC/2003	3507046	Inverness Medical - Biostar Inc.	10/JUN/2013
BST0011	JP	03/AUG/2001	2001-236186	27/FEB/1996	5494829	Inverness Medical - Biostar Inc.	27/FEB/2013
BST0011	US	10/JUN/1993	08075128	20/MAY/1997	5531171	Inverness Medical - Biostar Inc.	20/MAY/2016
BST0013	US	20/MAR/1996	08/619961	09/MAY/2000	6060237	Inverness Medical - Biostar Inc.	20/MAR/2016
BST0020	US	17/JAN/1995	08/375151	12/MAR/2002	6355429	Inverness Medical - Biostar Inc.	09/MAY/2017
BST0020	US	21/OCT/1999	09/425072	31/AUG/2004	6789938	Inverness Medical - Biostar Inc.	17/JAN/2015
BST0020	US	18/OCT/2001	09/862658	09/SEP/1996	5552272	Inverness Medical - Biostar Inc.	03/SEP/2013
BST0021	US	10/JUN/1993	08076348	30/JUL/1996	5641057	Inverness Medical - Biostar Inc.	30/JUL/2013
BST0022	US	10/JUN/1993	08075952	15/JUN/2005	69434406.0	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	DE	02/DEC/1994	94308983.9			Inverness Medical - Biostar Inc.	

BST0023	EP	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	ES	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	FR	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	GB	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	HK	02/DEC/1994	94308983.9	23/SEP/2005	1001885	Inverness Medical - Biostar Inc.	02/DEC/2014
BST0023	IT	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.	03/DEC/2013
BST0023	US	03/DEC/1993	08162401	27/FEB/1996	5494801	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	AU	21/JUN/1999	49603/99	26/SEP/2002	747986	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	CA	21/JUN/1999	2334584	03/MAY/2005	2334584	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	CN	21/JUN/1999	9806819.5	07/APR/2004	9806819.5	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	DE	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	EP	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	ES	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	FR	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	GB	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	HK	21/JUN/1999	01107099.4	30/SEP/2004	1036236	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	IN	21/JUN/1999	IN/PCT/2000/00662			Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	IT	21/JUN/1999	99933568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	JP	21/JUN/1999	2004-297557			Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	JP	21/JUN/1999	2000-558849	16/FEB/2007	3916889	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	MY	22/JUN/1999	P19902560	28/JAN/2006	121411A	Inverness Medical - Biostar Inc.	28/JAN/2021
BST0024	SG	21/JUN/1999	200007494.8	30/JUN/2003	78192	Inverness Medical - Biostar Inc.	21/JUN/2019
BST0024	TW	24/JUN/1999	89110561	20/FEB/2001	NI-121230	Inverness Medical - Biostar Inc.	24/JUN/2014
BST0024	US	28/JUN/1998	09105309	18/JUL/2000	6090572	Inverness Medical - Biostar Inc.	28/JUN/2018
BST0024	US	17/JUL/2000	09/617394	27/MAR/2001	6207445	Inverness Medical - Biostar Inc.	28/JUN/2018
BST0025	AU	06/MAR/2000	3727100	20/AUG/2004	772885	Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	CA	06/MAR/2000	2366307			Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	CN	06/MAR/2000	00805077.5			Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	EP	06/MAR/2000	00816114.2			Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	HK	06/MAR/2000	02104875.0			Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	IN	06/MAR/2000	IN/PCT/2001/00968	02/JUN/2006	189289	Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	JP	06/MAR/2000	2000-605207			Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	KR	06/MAR/2000	10-2001-7011848	19/JAN/2007	0674525	Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	SG	06/MAR/2000	200105414.7	28/NOV/2003	83390	Inverness Medical - Biostar Inc.	06/MAR/2020
BST0025	TW	06/APR/2000	89104986	11/DEC/2001	NI-148428	Inverness Medical - Biostar Inc.	06/APR/2015
BST0025	US	18/MAR/1999	09/272641	11/SEP/2001	6287783	Inverness Medical - Biostar Inc.	18/MAR/2019
BST0025	US	12/JUL/2001	09/905146	03/AUG/2004	6770447	Inverness Medical - Biostar Inc.	18/MAR/2019
BST0026	CN	03/AUG/2000	00812202.4			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0026	EP	03/AUG/2000	00852567.6			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0026	JP	03/AUG/2000	2001-515978	30/JUN/2006	3623053	Inverness Medical - Biostar Inc.	03/AUG/2020
BST0026	JP	03/AUG/2000	2005-373906			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0026	KR	03/AUG/2000	10-2002-7001601			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0026	TW	26/SEP/2000	89115787	29/JAN/2007	0675696	Inverness Medical - Biostar Inc.	26/SEP/2020
BST0026	US	03/AUG/2000	09/632343	11/JAN/2003	NI-169901	Inverness Medical - Biostar Inc.	03/AUG/2020
BST0027	AU	20/OCT/1997	49129/97	02/DEC/2003	5656428	Inverness Medical - Biostar Inc.	20/OCT/2017
BST0027	EP	20/OCT/1997	97811850.2	09/AUG/2001	732463	Inverness Medical - Biostar Inc.	20/OCT/2017
BST0027	HK	20/OCT/1997	99105266.6			Inverness Medical - Biostar Inc.	20/OCT/2017
BST0027	ID	20/OCT/1997	VI-990278	22/DEC/2003	ID0012334	Inverness Medical - Biostar Inc.	20/OCT/2017

BST0027	JP	20/OCT/1997	1998-520567	23/APR/2004	3547454	Inverness Medical - Biostar Inc.	20/OCT/2017
BST0027	JP	20/OCT/1997	2003-312436	12/JAN/2007	3900289	Inverness Medical - Biostar Inc.	20/OCT/2017
BST0027	TW	30/OCT/1997	86116219	21/JUN/2004	NI-203864	Inverness Medical - Biostar Inc.	31/OCT/2016
BST0027	US	15/OCT/1997	08/850963	26/DEC/2006	7153651	Inverness Medical - Biostar Inc.	31/OCT/2016
BST0027	US	29/SEP/2000	09/675518	23/AUG/2005	6933112	Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	AU	17/DEC/1999	21941/00	03/JUN/2004	770194	Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	CN	17/DEC/1999	200710135987.8			Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	CN	17/DEC/1999	99815096.7			Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	EP	17/DEC/1999	99966392.5			Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	HK	17/DEC/1999	02100371.7			Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	IN	17/DEC/1999	281/DELNP/2006			Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	JP	17/DEC/1999	2006-328455			Inverness Medical - Biostar Inc.	28/JAN/2021
BST0028	MY	21/DEC/1999	P19905641	28/JAN/2006	MY-121411-A	Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	SG	17/DEC/1999	200103852.0	29/AUG/2003	81760	Inverness Medical - Biostar Inc.	17/DEC/2019
BST0028	TW	17/DEC/1999	88122268	11/DEC/2001	NI-146232	Inverness Medical - Biostar Inc.	29/DEC/2018
BST0028	US	29/DEC/1998	09/223066			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	CN	03/AUG/2000	00811055.7	22/MAR/2006	00811055.7	Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	CN	03/AUG/2000	200510085540.5			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	EP	03/AUG/2000	00953853.9			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	IN	03/AUG/2000	IN/PT/2002/00181			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	JP	03/AUG/2000	2004-218193			Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	JP	03/AUG/2000	2001-515920	10/FEB/2005	3645523	Inverness Medical - Biostar Inc.	03/AUG/2020
BST0030	KR	03/AUG/2000	10-2002-7001557			Inverness Medical - Biostar Inc.	04/AUG/2020
BST0030	US	04/AUG/2000	09/633036	19/NOV/2002	6483565	Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	CN	14/APR/2004	200480010302.1			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	EP	14/APR/2004	04750150.7			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	HK	14/APR/2004	05102354.0			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	IN	14/APR/2004	3751/DELNP/2005			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	JP	14/APR/2004	2006-510051			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	KR	14/APR/2004	10-2005-7019594			Inverness Medical - Biostar Inc.	14/APR/2024
BST0032	US	16/APR/2003	10/417883			Inverness Medical - Biostar Inc.	16/APR/2023
BST0029	ES	21/SEP/1999	146394	06/JUL/2000	146394	Inverness Medical - Biostar Inc.	06/JUL/2020
BST0029	JP	22/MAR/1999	11-025681	06/APR/2001	1170979	Inverness Medical - Biostar Inc.	10/OCT/2014
BST0029	US	22/MAR/1999	29/102418	10/OCT/2000	D431867	Inverness Medical - Biostar Inc.	02/OCT/2023
ISC0008	US	02/OCT/2003	10/680935			ischemia Technologies, Inc.	02/OCT/2023
ISC0009	US	02/OCT/2003	10/679699			ischemia Technologies, Inc.	02/OCT/2018
ISC0003	US	02/OCT/1998	09/185926	08/OCT/2002	6461875	ischemia Technologies, Inc.	02/OCT/2018
ISC0004	US	02/OCT/1998	09/165581	10/DEC/2002	6492179	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	AT	10/JUL/1992	92915563.8	09/MAR/2005	0596925	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	AU	10/JUL/1992	10006/97	26/AUG/1999	705300	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	BE	10/JUL/1992	92915563.8	09/MAR/2005	0596925	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	BR	10/JUL/1992	P19206312.8	02/MAY/2001	P19206312.8	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	CA	10/JUL/1992	2113266	10/JAN/2006	2113266	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	CH	10/JUL/1992	92915563.8	09/MAR/2005	0596925	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	DE	10/JUL/1992	92915563.8	09/MAR/2005	69233487.4	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	DK	10/JUL/1992	92915563.8	09/MAR/2005	0596925	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	EP	10/JUL/1992	92915563.8	09/MAR/2005	0596925	ischemia Technologies, Inc.	10/JUL/2012
ISC0005	EP	01/DEC/2003	03027486.4			ischemia Technologies, Inc.	10/JUL/2012

ISC0014	AU	29/APR/2002	2002308530	03/AUG/2004	6770487	ischemia Technologies, Inc.	29/APR/2022
ISC0014	CA	29/APR/2002	2446329			ischemia Technologies, Inc.	29/APR/2022
ISC0014	EP	29/APR/2002	02766865.6			ischemia Technologies, Inc.	29/APR/2022
ISC0014	JP	29/APR/2002	2002-585988			ischemia Technologies, Inc.	01/MAY/2021
ISC0014	US	01/MAY/2001	09/046411			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	AU	05/MAY/2004	2004240557			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	CA	05/MAY/2004	2524530			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	CN	05/MAY/2004	200480013619.0			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	EP	05/MAY/2004	04751679.4			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	HK	05/MAY/2004	06110013.6			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	IL	05/MAY/2004	171781			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	IN	05/MAY/2004	2131/KOLNP/2005			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	JP	05/MAY/2004	2006-532878			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	KR	05/MAY/2004	2005-7020921			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	NZ	05/MAY/2004	543538			ischemia Technologies, Inc.	05/MAY/2024
ISC0015	SG	05/MAY/2004	200507034.7			ischemia Technologies, Inc.	14/MAY/2024
ISC0015	US	19/MAY/2003	10/441155	11/JUL/2006	7074194	ischemia Technologies, Inc.	19/MAY/2023
ISC0015	US	22/DEC/2005	11/317831			ischemia Technologies, Inc.	23/JAN/2026
ISC0016	EP	23/JAN/2006	06719258.3			ischemia Technologies, Inc.	20/APR/2013
SELF0001	US	10/MAR/1998	29/084813			Selfcare	04/APR/2014
SELF0001	US	24/SEP/1988	094066			Selfcare	

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

D. REGISTERED TRADEMARKS

[Include Owner, Registration Number and Date]

E. TRADEMARK APPLICATIONS

[Include Owner, Application Number and Date]

F. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 29, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedules IA, IB and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedules IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

~~BIOSITE INCORPORATED~~

By: 

Name: David Teitel
Title: Treasurer

Approved
As To Form


Legal Department

[SIGNATURE PAGE TO SECOND LIEN COUNTERPART TO IP SECURITY AGREEMENT]

LEGAL_US_E # 75512367

TRADEMARK
REEL: 004166 FRAME: 0030

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Biosite Incorporated as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of June 29, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Biosite Incorporated only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents.

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polypeptides Related to Natriuretic Peptides and Methods of their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	2522709 04/19/2004	
Polypeptides Related to Natriuretic Peptides and Methods of Their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	10/827919 04/19/2004	
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/453234 12/01/1999	6794132 09/21/2004
Human Antibodies	Lonberg, Nils Buechler, Joe Gray, Jeff Valkirs, Gunars E.	10/111365 04/01/2002	7135287 11/14/2006
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/521060 09/13/2006	
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/456090 12/06/1999	6680209 01/20/2004
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	10/149737 06/06/2002	7189515 03/13/2007
Human Antibodies as Detection Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/685068 03/12/2007	
Assays and Kits for Detecting Analytes In the Presence of Cross-Reacting Substances	Valkirs, Gunars E.	08/006341 01/19/1993	5914241 06/22/1999
Methods for Concentrating Ligands Using Magnetic Particles	Valkirs, Gunars E.	09/054918 04/03/1998	6348318 02/19/2002
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	08/832985 04/04/1997	6057098 05/02/2000
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/563055 05/01/2000	6986986 01/17/2006

TRADEMARK

REEL: 004166 FRAME: 0034

Title	Inventor	Application No.	Patent No. Issue Date
Polyclonal Libraries	Gray, Jeff Buechler, Joe Valkirs, Gunars E.	08/835159 04/04/1997	655310 04/29/2003
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	08/832935 04/04/1997	595375 10/12/1999
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	09/363960 07/29/1999	650372 01/07/2003
Recombinant Library Screening Methods	Dower, William J. Cwiria, Steven E.	07/517659 05/01/1990	5427908 06/27/1995
Recombinant Library Screening Methods	Dower, William J. Cwiria, Steven E.	08/376326 01/20/1995	5580717 12/03/1996
RECOMBINANT LIBRARY SCREENING METHODS	Dower, William J. Cwiria, Steven E.	08/450754 05/25/1995	
DIAGNOSTIC ASSAY FOR DETECTION OF CRYPTOSPORIDIUM PARVUM	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/158180 09/21/1998	
Diagnostic Assays for Detection of Cryptosporidium Parvum	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/877933 06/07/2001	7052858 05/30/2006
Diagnostic Assays for Detection of Giardia Lambia	Buechler, Joe Govindaraj, Shanthi Gray, Jeff Valkirs, Gunars E.	10/155163 05/23/2002	6908739 06/21/2005
Diagnostic Assays for Detection of Entamoeba Histolytica	Valkirs, Gunars E. Buechler, Joe Gray, Jeff	09/158347 09/21/1998	6207395 03/27/2001
Chimeric Polyclonal Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/410903 10/02/1999	6420113 07/16/2002
Chimeric Polyclonal Antibodies	Buechler, Joe	10/193960 07/12/2002	
Use of a Tag to Enrich Polypeptides Libraries	Buechler, Joe Valkirs, Gunars Gray, Jeff	11/015628 12/16/2004	
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	09/754947 01/04/2001	6828110 12/07/2004

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	10/890083 07/12/2004	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/339744 01/08/2003	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/447300 05/27/2003	
Compositions and Methods for Phage Display of Polypeptides	Gray, Jeff Valkirs, Gunars E.	11/198920 08/05/2005	
Latent Protein C Assays and Their Uses for Diagnosis and/or Prognosis in Systemic Inflammatory Response Syndromes	Valkirs, Gunars E. Buechler, Joe	11/614836 12/21/2006	
High Sensitivity Secretagogin Assays and Their Uses for Diagnosis and/or Prognosis	Buechler, Joe Nakamura, Kevin	11/654901 01/17/2007	

TITLE	INVENTORS	CNTRY	SERIAL NO./ FILING DATE	REG NO./ REG. DATE
Devices and Methods for Performing Receptor Binding Assays Using Magnetic Particles	John Michael Anderberg David M. Gregory	USA	60/834,073 07/28/2006	
Methods and Compositions For Monitoring And Risk Prediction in Cardiorenal Syndrome	Gunars Valkirs Paul H. McPherson	USA	60/859,137 11/14/2006	
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome	Gunars Valkirs Paul H. McPherson	USA	60/891,342 02/23/2007	
Method and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis	Gunars Valkirs Paul H. McPherson	USA	60/859,136 11/14/2006	

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	11/512743	8/29/2006			USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
United States of America	11/684498	3/9/2007			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF DISEASES OF THE AORTA
United States of America	11/752135	5/22/2007			USE OF NATRIURETIC PEPTIDES AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	07/583738	10/10/1990	5091512	2/25/1992	Fibrinogen-specific monoclonal antibody
United States of America	07/364053	6/8/1989	5120834	6/9/1992	Fibrin-specific monoclonal antibody
United States of America	07/835800	2/14/1992	5223410	6/29/1993	Method for production of antibodies using an antigen-free animal
United States of America	07/295568	1/10/1989	5028535	7/2/1991	THRESHOLD LIGAND RECEPTOR ASSAY
United States of America	08/284035	8/1/1984	5679526	10/21/1987	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	08/871900	6/11/1987	5939272	8/17/1999	NON-COMPETITIVE THRESHOLD LIGAND-RECEPTOR ASSAYS
United States of America	08/458276	6/2/1995	5922615	7/13/1999	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	09/249321	2/11/1999	6297060	10/2/2001	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	07/463150	1/10/1990	5089391	2/18/1992	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	07/583046	9/14/1990	5143852	9/1/1992	ANTIBODIES TO LIGAND ANALOGUES AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	07/808515	12/16/1991	5233042	8/3/1993	NOVEL COCAINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE COCAINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864110	4/6/1992	5414085	5/9/1995	NOVEL BARBITURATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BARBITURATE DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	07/864108	4/6/1992	5470997	11/28/1995	AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864106	4/6/1992	5237057	8/17/1993	NOVEL TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	08/032598	3/17/1993	5302703	4/12/1994	TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864093	4/6/1992	5302715	4/12/1994	NOVEL BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BENZODIAZEPINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864104	4/6/1992	5331109	7/19/1994	PHENCYCLIDINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PHENCYCLIDINE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/241061	5/11/1994	6777190	8/17/2004	CROSSTALK INHIBITORS AND THEIR USES
United States of America	08/101677	8/3/1993	5525524	6/11/1996	CROSSTALK INHIBITORS AND THEIR USES
United States of America	07/887526	5/21/1992	5458852	10/17/1995	DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF A REAGENT WITHOUT MEMBRANES
United States of America	08/447895	5/23/1995	6019944	2/1/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/447981	5/23/1995	5885527	3/23/1999	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/828041	3/27/1997	6156270	12/5/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/902775	7/30/1997	6271040	8/7/2001	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/810569	3/3/1997	6143576	11/7/2000	NON-POROUS DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS
United States of America	09/613650	7/11/2000			DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/805653	3/13/2001	6767510	7/27/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/982629	10/18/2001	6905882	6/14/2005	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/697351	10/29/2003			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/792258	3/2/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	11/022297	12/22/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/416034	4/3/1995	5710256	1/20/1998	METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/973997	11/91/1992	6037455	3/14/2000	PROPOXYPHENE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PROPOXYPHENE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/071203	6/1/1993	5480792	1/2/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/458901	6/2/1995	5985579	11/16/1999	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/101782	8/3/1993	5851776	12/22/1998	CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS
United States of America	08/311098	9/23/1994	5763189	6/9/1998	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN MICROPARTICLES USING NOVEL COMPOUNDS
United States of America	08/409298	3/23/1995	6251687	6/26/2001	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS
United States of America	08/389969	2/15/1995	5610283	3/11/1997	OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATION AND LABELS
United States of America	08/423582	4/18/1995	5795725	8/18/1998	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/653248	4/18/1996	6174686	1/16/2001	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	08/769077	12/18/1996	6627404	9/30/2003	METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	09/349194	7/7/1999	6939678	9/6/2005	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/425318	10/21/1999	6579687	6/17/2003	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/687051	10/12/2000	6991907	1/31/2006	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	10/459006	6/10/2003			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	10/850954	5/21/2004			NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	11/673397	2/9/2007			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	08/517949	8/22/1995	6803040	10/12/2004	DERIVATIVES OF TRICYCLIC ANTIDEPRESSANTS AND PROTEIN AND POLYPEPTIDE TRICYCLIC ANTIDEPRESSANT DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/704804	8/26/1996	6391265	5/21/2002	DEVICES INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	10/153423	5/21/2002			DEVICES FOR INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	08/620597	3/22/1996	5824799	10/20/1998	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	09/776599	2/1/2001	7083984	8/1/2006	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/274534	7/12/1994	6238931	5/29/2001	FLUORESCENCE ENERGY TRANSFER AND PARTICLES
United States of America	09/066255	4/24/1998	6964844	11/15/2005	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	11/449613	6/6/2006			HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/749702	11/15/1996	6113855	9/5/2000	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	09/612815	7/10/2000	6669907	12/30/2003	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	10/746282	12/24/2003			DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	08/837309	4/9/1997	6544797	4/8/2003	COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	10/338182	1/7/2003			NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	09/081722	5/13/1998	6670196	12/30/2003	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	10/697356	10/29/2003	7202042	4/10/2007	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	08/821888	3/21/1997	5947124	9/7/1999	DIAGNOSTIC FOR DETERMINING THE TIME OF A HEART ATTACK
United States of America	08/942370	10/21/1997	6106779	8/22/2000	A LYSIS CHAMBER FOR USE IN AN ASSAY DEVICE
United States of America	09/003066	1/5/1998	6074616	6/13/2000	MEDIA CARRIER FOR AN ASSAY DEVICE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	09/545699	4/6/2000	6392894	5/21/2002	MEDIA CARRIER FOR AN ASSAY DEVICE
United States of America	07/299277	1/23/1989	5202234	4/13/1993	MYOCARDIAL INFARCTION ASSAY
United States of America	07/882299	5/13/1992	5326692	7/5/1994	FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT
United States of America	09/358130	7/20/1999	6302919	10/16/2001	REVERSE-FLOW CENTRIFUGAL FILTRATION METHOD
United States of America	11/204764	8/15/2005			USE OF A GLUTATHIONE PEROXIDASE 1 AS A MARKER IN CARDIOVASCULAR CONDITIONS
United States of America	09/003090	1/5/1998	6830731	12/14/2004	IMMUNOASSAY FLUOROMETER
United States of America	10/267232	10/8/2002			IMMUNOASSAY FLUOROMETER
United States of America	10/841274	5/7/2004			IMMUNOASSAY FLUOROMETER
United States of America	09/003065	1/5/1998	6194222	2/27/2001	METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	09/712615	11/13/2000			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	11/676032	2/16/2007			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	08/993750	12/19/1997	6156521	12/5/2000	METHODS FOR THE RECOVERY AND MEASUREMENT OF TROPONIN COMPLEXES
United States of America	09/835298	4/13/2001			USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/389720	3/13/2003			USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/225082	8/20/2002			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/371149	2/20/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/673077	9/26/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/714078	11/14/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF
United States of America	10/875800	6/23/2004			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/330696	12/27/2002			MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/728067	12/3/2003			USE OF THROMBUS PRECURSOR PROTEIN AND MONOCYTE CHEMOATTRACTANT PROTEIN AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	10/952275	9/27/2004			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS
United States of America	11/022552	12/23/2004			METHODS AND COMPOSITIONS FOR DETERMINING TREATMENT REGIMENS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	10/759216	1/20/2004			BIOMARKERS FOR SEPSIS
United States of America	11/543312	10/3/2006			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/690767	3/23/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/770608	6/28/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America					ARGININE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/139086	5/4/2002			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	11/205571	8/17/2005			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	10/331127	12/27/2002			METHOD AND SYSTEM FOR DISEASE DETECTION USING MARKER COMBINATIONS
United States of America	10/410572	4/8/2003			SYSTEM AND METHOD FOR IDENTIFYING A PANEL OF INDICATORS
United States of America	10/603891	6/24/2003			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	11/737621	4/19/2007			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/419059	4/17/2003			POLYPEPTIDES RELATED TO NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE
United States of America	10/645874	8/20/2003			METHODS AND COMPOSITIONS FOR MEASURING BIOLOGICALLY ACTIVE NATRIURETIC PEPTIDES AND FOR IMPROVING THEIR THERAPEUTIC POTENTIAL
United States of America	10/938760	9/9/2004			METHODS AND COMPOSITIONS FOR MEASURING NATRIURETIC PEPTIDES AND USES THEREOF
United States of America	11/560425	11/16/2006			COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION
United States of America	11/222494	9/7/2005			METHODS AND COMPOSITIONS FOR MEASURING CANINE BNP AND USES THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/778919	2/12/2004	6887952	5/3/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/080211	3/14/2005	6967107	11/22/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/184746	7/19/2005			N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/450150	6/9/2006			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLIC DISEASE

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks.

COUNTRY	TRADEMARK	CLASS(ES)	APPL. NO FILING DATE	REG NO. ISSUE DATE
US	AN UNFAIR ADVANTAGE	1, 42	75/609619 12/21/1998	2453707 05/22/2001
US	BIOSITE DISCOVERY AN UNFAIR ADVANTAGE & Design	1, 5, 42	75/655110 03/05/1999	2456030 05/29/2001
US	OMNICLONAL	1, 5	75/609841 12/21/1998	2476239 08/07/2001

TRADEMARK

REEL: 004166 FRAME: 0049

MARK	COUNTRY	SERIAL NO. FILING DATE	REG. NO./ REG. DATE
MULTI-MARKER INDEX	USA	78/574,678 02/24/2005	

Biosite (U.S. only)

Docket Number	Country	Mark	Portfolio Status	Owner	Application No.	Application Date	Registration Date	Registration Number
071949-4501	United States of America	IN TIME TO DECIDE	Registered	Biosite Inc	78/056518	4/3/2001	7/30/2002	2601205
071949-4601	United States of America	NEW DIMENSIONS IN DIAGNOSIS	Registered	Biosite Inc	78/072981	7/9/2001	8/26/2003	2757467
071949-4701	United States of America	ASCEND MULTIMUNOASSAY	Registered	Biosite Inc	74/489582	2/14/1994	10/3/1995	1923243
071949-4801	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260208	3/30/1992	9/28/1993	1794618
071949-4802	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260475	3/30/1992	10/5/1993	1796567
071949-4819	United States of America	BIOSITE and Design	Registered	Biosite Inc	76/634473	3/28/2005	10/10/2006	3152581
071949-5101	United States of America	TRIAGE	Registered	Biosite Inc	74/525008	5/16/1994	2/6/1996	1954150
071949-5202	United States of America	TpP Stylized	Registered	Biosite Inc	75/172105	9/26/1996	1/14/2003	2673476
071949-6401	United States of America	EXPRESS TEST	Registered	Biosite Inc	75/075619	3/20/1996	12/1/1998	2207727
071949-6402	United States of America	EXPRESS TEST and Design	Registered	Biosite Inc	75/099733	5/2/1996	9/21/1999	2279640
071949-6101	United States of America	CARDIO PROFILER	Registered	Biosite Inc	78/178159	10/24/2002	6/7/2005	2960760

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

The following Supplemental Schedules (the "*Schedules*") of the Grantors with respect to that certain Second Lien Intellectual Property Security Agreement among the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*") are being delivered pursuant to Section 7 of Schedule 7.15 to the Second Lien Credit Agreement by and among the Borrower, Holdings, the Lenders party thereto, General Electric Capital Corporation, as Administrative Agent, UBS Securities LLC, as Syndication Agent, Joint Lead Arranger and Sole Bookrunner, and GE Capital Markets, Inc., as Joint Lead Arranger dated as of June 26, 2007. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement. The Schedules give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Quality Assured Services, Inc., only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks - Quality Assured Services, Inc.

Name of Mark	Serial Number	Status
Cafe PTINR	78857466	Approved 04-10-2007
QAS	78857429	Pending Approval (Published for opposition)
INRCare	78810066	Pending Approval (Published for opposition)
Town Hall Meeting	78867671	Pending Approval (Published for opposition)
The Best Way to Test	77030923	Pending Approval
IN-Range	78866759	Abandoned
Vitamin K Registry	78866731	Abandoned
PTINR.COM	78857424	Allowed for Registration on Supplemental Register
Vitamin K Food Diary	78866740	Allowed for Registration on Supplemental Register

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of August [15], 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

DIAMICS, INC

By: 

Name: Peter Gombrich

Title: Chairman and CEO

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Diamics, Inc. as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of August 15, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of certain of the capital stock of Diamics, Inc. only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.


SCHEDULE 1A
TO
SECOND
~~FIRST~~ LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights - None

SCHEDULE 1B
TO
SECOND
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

See attached list of patents.

CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS



CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS

New claim added to U.S. system application

A system comprising:
means for collecting and maintaining the spatial orientation of cervical cell clusters;
means for transferring a sample of the collected cell clusters onto a slide while maintaining the spatial orientation of the transferred sample and without changing or destroying the morphological aspects of the transferred sample; and
a container with preservative for receiving the remaining collected cervical cell clusters, the preservative maintaining the morphological aspects of the remaining cell clusters and their antigenicity.

ASSAY FOR INDICATING A CELL TISSUE CONDITION PATENT

Provisional application
60/885146
Filed Jan. 16, 2007

POINT OF CARE CERVICAL SCREENING SYSTEM

Provisional application
60/939533
Filed May 22, 2007

SECOND
**SCHEDULE 1C
TO
~~FIRST~~ LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks.

TRADEMARKS

CYSAVE
SN 78/748299
Filed 11/7/05
Stat: Allowed

CYSPRAY
SN 78/748247
Filed 11/7/05
Stat: Allowed

C-MAP
SN 78/799137
Filed 1/25/06
Stat: Allowed

CER-COL
SN 78/799144
Filed 1/25/06
Stat: Allowed


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of October 12, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

CHOLESTECH CORPORATION

By: 

Name: David Tenet

Title: Vice President Finance

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT - CHOLESTECH CORPORATION - SECOND LIEN]
LEGAL_US_E # 76561878

TRADEMARK
REEL: 004166 FRAME: 0066

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Cholestech Corporation as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of October 12 2007 and give effect to, and contain data relating to, the acquisition by Inverness Medical Innovations, Inc. of certain of the capital stock of Cholestech Corporation only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Issued Patents:

PATENT NUMBER	TITLE	ISSUE DATE	EXPIRATION DATE	COUNTRIES GRANTED
US 5,110,72	Multi-Analyte Assay Device	5/05/92	5/05/09	U.S.
US 5,114,350	Controlled-Volume Assay Apparatus	5/19/92	5/19/09	U.S.
US 5,156,964	Assay Device and Method using a Signal Modulating Compound	10/20/9	10/20/09	U.S.
US 5,171,688	Self-Correcting Assay Device	12/15/92	12/15/09	U.S.
US 5,213,965	Solid-Phase Precipitation Assay Device	5/25/93	5/25/10	U.S., PCT, Japan, Korea, Australia
US 5,213,964	High-Density Lipoprotein Solid-Phase Precipitation Assay Method	5/25/93	5/25/10	U.S. PCT, Japan, Korea, Australia
US 5,316,916	HDL Solid Phase Assay Device	5/31/94	5/31/11	U.S. PCT, Japan, Korea, Australia
US 5,451,370	High Density Lipoprotein Assay Device and Method	4/19/05	4/19/22	U.S., PCT, Japan
US 7,220,595	Automated Immunoassay Cassette,	5-22-07		US

Pending Applications:

PATENT APPLICATION NUMBER	TITLE	FILING DATE
20040235182	Adhered Membranes Retaining Porosity and Biological Activity	4/02/03
Unpublished	Novel Algorithm to measure LDL Cholesterol	1/07
20050221502	Assay System and Method for Direct Measurement of LDL Cholesterol	4/02/04
20030224471	High-Density Lipoprotein Assay Device and Method	4/9/02

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks:

TRADEMARK	COUNTRY	REGISTRATION NUMBER
Cholestech	Argentina	1.614.070
Cholestech	Australia	A589031
Cholestech	Benelux	526249
Cholestech	Brazil	818323957
Cholestech	Canada	430,654
Cholestech	France	92 443 221
Cholestech	Germany	2 066 360
Cholestech	Italy	00644845
Cholestech	Japan	3093467
Cholestech	Mexico	510537
Cholestech	Spain	1733685
Cholestech	Switzerland	531.830
Cholestech	United Kingdom	B1517230
Cholestech	United States of America	1,767,348
Cholestech GDx	Australia	936842
Cholestech GDx	European Community	296017
Cholestech GDx	Republic of Korea	579229
Cholestech GDx	Taiwan	91051354
Cholestech GDx	Taiwan	1066087
Cholestech GDx	United States of America	2,882,423
Cholestech L D X	Mexico	510536
Cholestech L D X	United States of America	1,705,798
Cholestech L*D*X	Argentina	1.643.621
Cholestech L*D*X	Brazil	818323949
Cholestech L.D.X	Benelux	526250
Cholestech L.D.X	France	92443220
Cholestech L.D.X	Germany	2,059,006
Cholestech L.D.X	Spain	1730024
Cholestech LDX	Italy	644846
Design (Cholestech Logo)	United States of America	1,799,242


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of December 6, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

HEMOSENSE, INC.

By: 

Name: David Teitel

Title: Treasurer

Approved
As To Form


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION
as Administrative Agent

By: 

Name:

Ryan Guenin

Title:

Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT - HEMOSENSE, INC. - SECOND LIEN]

LEGAL US F 77146002

TRADEMARK
REEL: 004166 FRAME: 0073

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of HemoSense, Inc. as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of December 6, 2007 and give effect to, and contain data relating to, the acquisition by Inverness Medical Innovations, Inc. of the capital stock of HemoSense, Inc. only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - See attached.

SCHEDULE 1B - PATENTS

Priority	Filing Date	Application No.	Patent No./ (Pub. Date)	Patent Date/ (Pub. Date)	Title	Inventor(s)	Status
US-ORD	9/14/06	11/532,072	Not yet published		Device and Method for Measuring Properties of a Sample	Farnam, W. Edward III Navarro, Maria Jina, Arvind N.	Pending; foreign filing due 09/14/07
US-ORD	6/27/97	US 08/884,027	US 6,046,051	04/04/00	Method and device for measuring blood coagulation or lysis by viscosity changes	Jina, Arvind N.	Issued; fourth year maintenance fee was paid; maintenance fee due 10/04/07
US-CON	11/9/98	US 09/195,842	US 6,060,323	05/09/00	Method and device for measuring blood coagulation or lysis by viscosity changes	Jina, Arvind N.	Issued; fourth year maintenance fee was paid; maintenance fee due 11/09/07
US-CON	1/15/99	US 09/231,731	US 6,066,504	05/23/00	Coagulation or lysis assays using an electroactive species	Jina, Arvind N.	Issued; fourth year maintenance fee was paid; maintenance fee due 11/23/07
US-DIV	4/4/00	US 09/542,886	US 6,338,821	01/15/02	Method and device for measuring blood coagulation or lysis by viscosity changes	Jina, Arvind N.	Issued; fourth year maintenance fee was paid; window for payment of eighth year maintenance fee opens on 01/15/09
US-CON	1/15/02	US 10/050,676	N/A	N/A	Method and device for measuring blood coagulation or lysis by viscosity changes	Confirm	Abandoned
US-CIP	1/15/99	US 09/232,768	US 6,673,622	01/06/04	Coagulation or lysis assays by measuring impedance	Jina, Arvind N.	Issued
PCT	7/29/98	PCT/US98/15801	(WO 00/06761)	(02/10/00)	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	30-month done
PCT-EP	7/29/98	EP 98939118	EP 1151268	12/22/04	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Granted; validated in FR, DE, IE, and GB
EP-FR	7/29/98	EP 98939118	FR 1151268	12/22/04	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Granted

Priority	Filing Date	Application No.	Patent No./ (Pub. Date)	Patent Date/ (Pub. Date)	Title	Inventor(s)	Status
EP-DE	7/29/98	EP 98939118	DE 68928319	12/22/04	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Granted
EP-IE	7/29/98	EP 98939118	IE 1151268	12/22/04	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Granted
EP-GB	7/29/98	EP 98939118	GB 1151268	12/22/04	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Granted
EP-DIV	7/29/98	EP 984076315	(EP 1482296)	(12/01/04)	Method and device for measuring blood coagulating or lysis by viscosity changes	Jina, Arvind N.	Pending; response to examination report due 09/04/07
US-ORD	5/31/07	11/756,582	Not yet published	Not yet published	Particle fraction determination of a sample	Greenquist, Alan C. McInerney, Margaret	Pending; response to notice to file missing parts due 09/05/07

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks - None


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of December ~~21~~²¹, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

ALERE MEDICAL, INC.

By: 

Name: David Teitel


Title: Vice President, Finance

**Approved
As To Form**


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION
as Administrative Agent

By: 
Name: _____
Title: Ryan Guenin
Duly Authorized Signatory

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Alere Medical, Inc., a California corporation ("Alere"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of December 21, 2007 and give effect to, and contain data relating to, the acquisition by Inverness Medical Innovations, Inc. of the capital stock of Alere, only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - See attached.

Schedule 1A - Copyrights

Registration No.	Title
TX4980607	Alere Nurse Station

B3445309.1

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - See attached.

Schedule 1B - Patents

COUNTRY	REFERENCE#	TYP	FILED	SERIAL#	ISSUED	PATENT	STATUS
METHOD AND DEVICE FOR DETECTING EDEMA							
UNITED STATES	ALER-003	NEW	10/28/1997	08/959,242	06/29/1999	5,915,386	ISSUED
METHOD AND DEVICE FOR DETECTING EDEMA							
UNITED STATES	ALER-002	NEW	10/28/1997	08/958,688	06/20/2000	6,077,222	ISSUED
METHOD AND DEVICE FOR DETECTING EDEMA							
UNITED STATES	ALER-004	NEW	10/28/1997	08/959,001	09/28/1999	5,957,867	ISSUED
UNITED STATES	ALER-004DIV	DIV	06/07/1999	09/327,153	02/13/2001	6,186,962	ISSUED
METHODS AND SYSTEMS FOR EVALUATING PATIENT DATA							
UNITED STATES	ALER-005(SP)	NEW	11/30/2004	11/001,667			ABANDONED
PATIENT INTERFACE SYSTEM WITH A SCALE							
UNITED STATES	ALER-001	NEW	10/28/1997	08/958,689	06/27/2000	6,080,106	ISSUED
UNITED STATES	ALER-001CIP	CIP	09/20/1999	09/399,982	06/25/2002	6,409,662	ISSUED

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks - See attached.

Schedule 1C - Trademarks

USPTO Serial No.	Mark	Type of Mark
78537021	PRAISE	Service Mark
78537096	HEART SMART SOLUTIONS	Trademark; Service Mark
75766963	ALERE	Trademark


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of January [11], 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

MILANO ACQUISITION CORP.

By: 
Name: David Teitel
Title: Vice President, Finance

Approved
As To Form


Legal Department

ACKNOWLEDGED AND AGREED


as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION
as Administrative Agent

By: _____

Name:

Title:


Ryan Guenin
Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT - MILANO ACQUISITION CORP. - SECOND LIEN]
LEGAL_US_E # 77846982

TRADEMARK
REEL: 004166 FRAME: 0092

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Milano Acquisition Corp., a Delaware corporation and wholly owned subsidiary of IM US Holdings, LLC ("*Milano*"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of January 11, 2008 and give effect to, and contain data relating to, the acquisition by Milano of substantially all the assets of Matritech, Inc., only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents

US Patents

U.S. Patent No.	Date Issued	Description
5,989,826	11/23/99	Claims to a method for detecting the presence of a cancer in an individual.
6,162,608	12/19/00	Claims to a method of detecting the presence of cancer in an individual.
6,410,247	6/25/02	Claims to a method for detecting the presence of a cancer in an individual.
6,740,494	5/25/04	Claims to a method for detecting the presence of a cancer in an individual.
5,965,376	10/12/99	Claims to methods for evaluating the cytotoxicity of a compound.
5,783,403	7/21/98	Claim to a method of detecting a malignant cell type, or determining the degree of cell death using a binding protein which recognizes MT1 or MT2.
5,882,876	3/16/99	Claims to a method of detecting the presence of a malignancy in a mammal, or to detecting a cancer in an individual using MT2 as a cancer marker.
5,698,439	12/16/97	Claims to nucleic acids, and vectors encoding MT1 and MT2, and host cells harboring such vectors.
5,686,562	11/11/97	Claims to isolated recombinant MT1 and MT2 proteins per se.
5,780,596	7/14/98	Claims to MT1-specific antibodies.
5,547,928	8/20/96	Claims to a protein marker for colon adenocarcinoma.
5,858,683	1/12/99	Claims directed to methods of detecting cervical cancer by detecting presence of TDP-43 marker.
6,027,905	2/22/00	Claims directed to method of detecting cervical cancer by detecting presence of IEF-SSP 9502 marker.
6,803,189	10/12/04	Claims directed to method of detecting cervical cancer by detecting presence of a nucleic acid encoding a cervical cancer-associated protein.

6,936,424	8/30/05	Claims directed to a method of detecting breast cancer by detecting the presence or amount of U2 SnRNPB" in a sample.
-----------	---------	---

Foreign Patents

Foreign Patent No.	Date Issued or Published	Description
AU 658257	7/24/95	Claims to a method for detecting the presence of a cancer in an individual.
CA 2,122,473	1/23/01	Claims to a method of detecting the presence of cancer in an individual.
EP 642668	4/5/00	Claims to a method for detecting the presence of a cancer in an individual.
JP 3,190,042	5/18/01	Claims to a method for detecting the presence of a cancer in an individual.
AU 681855	1/8/98	Claim to a method of detecting a malignant cell type, or determining the degree of cell death using a binding protein which recognizes MT2.
EP 0647270	1/7/04	Claim to a method of detecting a malignant cell type, or determining the degree of cell death using a binding protein which recognizes MT2.
CA 2,263,888	10/24/04	Claims directed to methods of detecting cervical cancer.
EP 0923740B1	7/5/06	Claims directed to methods of detecting cervical cancer.
EP 1232177	2/21/07	Claims directed to a method of detecting breast cancer by detecting the presence of amount of U2 SnRNPB" in a sample.

Patent Applications

Application No. or Serial No.	Jurisdiction	Date Applied	Description
11/194,051	US	7/29/05	Claims directed to method of detecting breast cancer.
11/232,440	US	9/21/05	Claims directed to method of screening for cancer by measuring or detecting U2 particle (U2 snRNA as species election), not B".
10-511706	JP	8/19/97	Claims directed to method of detecting cervical cancer.
2001-538959	JP	11/16/00	Claims directed to a method of detecting breast cancer by detecting the presence of amount of U2 SnRNPB" in a sample.
US05/33679	PCT	9/21/05	Claims directed to method of screening for cancer by measuring or detecting U2 particle (U2 snRNA as species election), not B".
05798983	EP	9/21/05	Claims directed to method of screening for cancer by measuring or detecting U2 particle (U2 snRNA as species election), not B".

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks

Mark	Country	Registration No.	Date Issued
BLADDERCHEK	EU	2,648,772	6/29/06
BLADDERCHEK	US	2,811,238	2/3/04
MATRITECH	EU	210,435	4/1/96
MATRITECH	US	2,766,248	9/23/03
MATRITECH	JP	4809188	10/8/04
MATRITECH	KR	40-577324	3/12/04
NMP22	EU	66,399	4/1/96
NMP22	US	1,956,141	2/13/96
NMP22	US	1,963,117	3/19/96
UNMP	JP	3,332,669	7/18/97
NMP179	EU	1,350,487	10/19/99
NMP179	US	2,838,902	5/4/04


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of January ~~24~~²⁴, 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

PARADIGMHEALTH, INC.

By: 
Name: David Teitel
Title: Vice President, Finance

Approved
As To Form


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT - PARADIGMHEALTH, INC. - SECOND LIEN]
LEGAL_US_E# 77941772

TRADEMARK
REEL: 004166 FRAME: 0102

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of ParadigmHealth, Inc., a Delaware corporation and wholly owned subsidiary of IM US Holdings, LLC ("*Paradigm Parent*"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of January 22, 2008 and give effect to, and contain data relating to, Paradigm Parent, pursuant to the acquisition by Inverness Medical Innovations, Inc. of capital stock of Paradigm Parent, only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights

The following copyright is registered in the name of NeuroCare, Inc. (predecessor company):

Title	Registration No.
NeuroCare East Bay programs community resource manual	TXu-284-426

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks

The following trademark is registered in the name of ParadigmHealth, Inc.:

Mark	Registration or Serial Number	Domain	Registration Date	Status	Attorney of Record
NEUROCARE INC. (And Design)	1,559,345	U.S.	10/03/89	Registered	Wilson Sonsini Goodrich & Rosati, P.C.


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of January ²⁹ 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

PARADIGM HEALTH SYSTEMS, INC.

By: 
Name: David Teitel
Title: Vice President, Finance

Approved
As To Form


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION
as Administrative Agent

By: 

Name:

Title:

Ryan Guenin
Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – PARADIGM HEALTH SYSTEMS, INC. – SECOND LIEN]
LEGAL_US_E # 77943351

TRADEMARK
REEL: 004166 FRAME: 0109

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Paradigm Health Systems, Inc., a Delaware corporation and wholly owned subsidiary of IM US Holdings, LLC ("*Paradigm Sub*"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of January 22, 2008 and give effect to, and contain data relating to, Paradigm Sub, pursuant to the acquisition by Inverness Medical Innovations, Inc. of capital stock of ParadigmHealth, Inc., parent of Paradigm Sub, only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights

The following copyrights are registered in the name of Paradigm Health Systems, Inc.:

Title	Registration No.	Registration Date
Thermoregulation for the NICU infant.	TX-5-337-917	2/20/2001
Apnea in premature infants : guidelines for treatment & discharge	TX-5-337-918	2/20/2001
Feeding of the high risk/low birth weight infant.	TX-5-337-919	2/20/2001
Family PReMi grids and activities.	TX-5 -337-920	2/20/2001
Care manager PReMi grids and activities.	TX-5-337-921	2/20/2001
Health appraisal status (HAS) score.	TX-5-337-922	2/20/2001
Discharge of the high risk/low birth weight infant.	TX-5-337-923	2/20/2001
Paidos grouper system : Paidos Health Management Services.	TX-5-367-020	3/2/2001
From NICU to home : caring for your special newborn.	TX-5-428-693	2/20/2001
Clinical management guidelines	TX-5-475-192	2/20/2001
Paidos report on neonatal practice, fall 2001.	TX-5-542-791	5/17/2002
Premature infant milestones : assessment of parent readiness for education	TX-5-546-642	5/17/2002
Baby steps.	TX-5-546-785	5/17/2002
Clinical management guidelines, April 2002	TX-5-554-009	6/21/2002
Neonatal practice benchmarks.	TX-5-73 1-759	6/21/2002
Paidos pasitos de bebe	TX-5-748-499	3/18/2003
Neonatal clinical management guidelines 2004	TX-6-121-694	02/28/2005
NICU care management: paradigmHealth's NICU solution	TX-6- 139-998	02/28/2005
NICU care management : paradigmHealth's national neonatal expertise	TX-6-140-001	02/28/2005
NICU care management: paradigmHealth's family support, education and feedback	TX-6-140-002	02/28/2005
Complex care management 2004 annual report	TX-6-170-036	02/28/2005

Baby steps : caring for your special newborn	TX-6-170-043	02/28/2005
Los pasos del bebe : cuida de su reci, n. nacido especial.	TX-6-170-044	02/28/2005

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents

The following patents are registered (or applications have been filed) in the name of PersonalPath Systems, Inc:

Title	Patent Number	Publication No.	Assignee
Method of customizing a browsing experience on a world-wide-web site	6,734,886	--	PersonalPath Systems, Inc.
Privacy and security method and system for a World-Wide-Web Site	--	20010054155	PersonalPath Systems, Inc.
Three party signing protocol providing non-linkability	--	20030190046	PersonalPath Systems, Inc.

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks

The following trademarks are registered in the name of Paradigm Health Systems, Inc., 10 Mountainview Road, Upper Saddle River, NJ 07458:

Mark	Serial No.	Filing Date	Status	Attorney of Record
LATITUDES	77/012,118	10/02/2006	Pending ITU	Orrick, Herrington & Sutcliffe LLP
VITRUVIUS	77/162,948	April 23, 2007	Pending	Orrick, Herrington & Sutcliffe LLP
VITRUVIUS	77162946	April 23, 2007	Pending	Orrick, Herrington & Sutcliffe LLP

The following trademarks are registered in the name of Paradigm Health Systems, Inc., 1001 Galaxy Way, Suite 300, Concord, CA 94520:

Mark	Registration No.	Registration Date	Status	Attorney of Record
PERSONAL PATH	2,494,773	10/02/2001	Registered	Winston & Strawn
PERSONALPATH.COM	2,493,488	09/25/2001	Registered	Winston & Strawn
UAI	2,729,549	06/24/2003	Registered	Whitman, Curtis & Christofferson PC
FRANKLIN HEALTH	2,673,563	01/14/2003	Registered	Whitman, Curtis & Christofferson PC
PARADIGMHEALTH	2,678,058	01/21/2003	Registered	Orrick
PERSONALPATH	2,613,146	08/27/2002	Registered	Whitman, Curtis & Christofferson PC


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of January 28, 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

RTL HOLDINGS, INC.


By: 
Name: David Teitel
Title: Vice President, Finance

Approved
As To Form


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name:
Title: Ryan Guenin
Duly Authorized Signatory

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of RTL Holdings, Inc. ("**RTL**"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "**Agreement**"). The Supplemental Schedules (the "**Schedules**") are dated as of January 25, 2008 and give effect to, and contain data relating to RTL pursuant to the acquisition by Inverness Medical Innovations, Inc. of the capital stock of RTL only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None.

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks - None.

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of January 28, 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

REDWOOD TOXICOLOGY LABORATORY, INC.

By: 
Name: David Teitel
Title: Vice President, Finance

Approved
As To Form


Legal Department


[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT -
REDWOOD TOXICOLOGY LABORATORY, INC. - SECOND LIEN]

LEGAL_US_E # 77846978

TRADEMARK
REEL: 004166 FRAME: 0123

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: _____
Title: Ryan Guenin
Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT --
REDWOOD TOXICOLOGY LABORATORY, INC. - SECOND LIEN]

LEGAL_US_E # 77846978

TRADEMARK
REEL: 004166 FRAME: 0124

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Redwood Toxicology Laboratory, Inc. ("**Redwood**"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "**Agreement**"). The Supplemental Schedules (the "**Schedules**") are dated as of January 25, 2008 and give effect to, and contain data relating to Redwood pursuant to the acquisition by Inverness Medical Innovations, Inc. of the capital stock of RTL Holdings, Inc., the parent of Redwood, only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None.

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks

US Trademarks

Mark	Country	Registration No.	Date Issued
PERMAXIM	US	3,180,037	12/5/06
REDITEST	US	3,031,790	12/20/05
REDWOOD BIOTECH RAPID ON-SITE DRUG DETECTION REDI SCREEN	US - CALIFORNIA	106,839	11/16/00

Trademark Applications

Mark	Country	Application No.	Date Applied
REDI-CLIN	US	78,708,397	9/7/05


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 13, 2008, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.


Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

MATRIA HEALTHCARE, LLC

By: 
Name: David Teitel
Title: Vice President

MATRIA HEALTH ENHANCEMENT
COMPANY
QUALITY ONCOLOGY, INC.
MIAVITA, INC.
WINNINGHABITS, INC.
WINNINGHABITS GP, INC.
WINNINGHABITS LP, INC.
MATRIA WOMEN'S AND CHILDREN'S
HEALTH, LLC
DIABETES ACQUISITION, INC.

By: 
Name: David Teitel
Title: Vice President, Finance

APPROVED
As To Form

Legal Department


[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – SECOND LIEN
MATRIA HEALTHCARE, LLC AND ITS SUBSIDIARIES]

LEGAL_US_E # 79393604

TRADEMARK
REEL: 004166 FRAME: 0130

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Duly Authorized Signatory

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – SECOND LIEN
MATRIA HEALTHCARE, LLC AND ITS SUBSIDIARIES]

LEGAL_US_E # 79393604

TRADEMARK
REEL: 004166 FRAME: 0131

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Matria Healthcare, LLC (formerly known as Matria Healthcare, Inc.) and certain of its subsidiaries (“*MATRIA*”), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the “*Agreement*”). The Supplemental Schedules (the “*Schedules*”) are dated as of June 13, 2008 and give effect to, and contain data relating to *MATRIA* only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights –

Copyrights owned by Matria Healthcare, LLC (formerly Matria Healthcare, Inc.)

Title	Reg. No.	Reg. Date
Trimester Magazine	TX 3-896-924	1994
Tokos Perinatal Policies and Procedures	TXu 302-098	1987

Copyrights owned by Matria Women's and Children's Health, LLC

Title	Reg. No.	Reg. Date
Evidence based medicine and continuous subcutaneous terbutaline infusion	TXu 1-122-073	2003
Evidence-based medicine and home uterine activity monitoring for tertiary prevention of preterm birth	TXu 1-125-254	2003

Copyrights owned by CorSolutions, Inc.

Title	Reg. No.	Reg. Date
Integrated health and productivity solutions.	TXu001209197	04/28/2005
Customer-centric health intelligence and solutions feature THE integrated approach to health and productivity	TXu001209198	04/28/2005
Achieving better control, a comprehensive diabetes self-management training program	TX 4-172-006	1996

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents -

Title	Patent Number	Domain	Owner
APPARATUS FOR RECORDING REAGENT TEST STRIP DATA BY COMPARISON TO COLOR LIGHTS ON REFERENCE PANEL	5,182,707	U.S.	Matria Healthcare, LLC (formerly known as Matria Healthcare, Inc.)
PREDICTIVE MODELING SYSTEM AND METHOD FOR DISEASE MANAGEMENT	11/200,804	U.S.	Matria Healthcare, LLC (formerly known as Matria Healthcare, Inc.)

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks –

Trademarks owned by Matria Healthcare, LLC (formerly Matria Healthcare, Inc.)

Mark	Registration or Serial Number	Domain	Registration Date	Status
BABYLINE	1,915,721	U.S.	08/29/1995	Registered
BABYLINK	3,004,269	U.S.	10/04/2005	Registered
BABY'S FEET LOGO (DESIGN ONLY)	1,913,309	U.S.	08/22/1995	Registered
CARELINK	1,556,290	U.S.	09/12/1989	Registered
CORADMINISTRATIVE CONNECTIONS	3,095,341	U.S.	05/23/2006	Registered
CORCHOICES	2,787,898	U.S.	12/02/2003	Registered
CORCONNECT	2,798,305	U.S.	12/23/2003	Registered
	2,981,916	U.S.	08/02/2005	Registered
CORDIMENSIONS	3,052,572	U.S.	01/31/2006	Registered
CORSOLUTIONS	2,523,336	U.S.	12/25/2001	Registered
GENESIS	1,499,423	U.S.	08/09/1988	Registered
HEALTHDYNE	294,029	Canada	08/10/1984	Registered
	1,183,590	U.S.	12/29/1981	Registered
MATERNALINK	2,277,168	U.S.	09/14/1999	Registered
MATRIA	2,053,608	U.S.	04/15/1997	Registered
MATRIA HEALTHCARE	2,053,602	U.S.	04/15/1997	Registered
MEASURABLY IMPROVING LIVES	3,049,857	U.S.	01/24/2006	Registered
NEOLINK	3427564	U.S.	05/13/2008	Registered
PERIDATA	1,579,562	U.S.	01/23/1990	Registered
SYSTEM 37	1,576,235	U.S.	01/09/1990	Registered

THE HEALTH ENHANCEMENT COMPANY	2,778,802	U.S.	10/28/2003	Registered
TMNS	3,437,205	U.S.	05/27/2008	Registered
TOTAL MATERNAL-NEWBORN SOLUTION	3,437,206	U.S.	05/27/2008)	Registered
TOUCHENGINE	77/467,746 (serial number)	U.S.	05/07/2008 (filed)	Pending
TOUCH ENGINE	77/467,743 (serial number)	U.S.	05/07/2008 (filed)	Pending
TRIMESTER	1,913,308	U.S.	08/22/1995	Registered
VOICE CONNECTIONS	3,302,657	U.S.	10/02/2007	Registered
WELL FOCUS	2,664,086	U.S.	12/17/2002	Registered
WINDOW OF CARE	2,931,729	U.S.	03/08/2005	Registered
WINNINGHABITS.COM	2,594,975	U.S.	07/16/2002	Registered
	2,579,444		6/11/2002	

Trademarks owned by Quality Oncology, Inc. (subsidiary of Matria Healthcare, LLC)

Mark	Registration or Serial Number	Domain	Registration Date	Status
CANCER PAGE.COM	2,545,314	U.S.	03/05/2002	Registered
CANCERPAGE.COM (AND DESIGN)	001800788	E.U.	01/21/2002	Registered
	1068914 (application number)	Canada	07/27/2000	Searched
	2,919,216	U.S.	01/18/2005	Registered

Trademarks owned by Miavita, Inc. (subsidiary of Matria Healthcare, LLC)

Mark	Registration or Serial Number	Domain	Registration Date	Status
MIAVITA	2646360	U.S.	11/05/2002	Registered.

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of February 3, 2009, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

AMEDITECH INC.


By: 

Name: David Teitel

Title: General Manager


APPROVED

As To Form


Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Its Authorized Signatory

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Ameditech Inc. ("*Ameditech*"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of February 3, 2009 and give effect to, and contain data relating to Ameditech only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights -

None


**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents -

Description	Patent Number
Fluid-Specimen Collecting and Testing Device and Method for Recording Chromatographic Assay Test Results	U.S. 7,300,626 B2
Dual-Chambered Fluid-Specimen Testing Device and Method	U.S. 6,726,879 B2
Fluid-Specimen Collecting and Testing Device and Method for Recording Chromatographic Assay Test Results	US2008/0056941 (Pending)
Fluid Sample Collecting and Analyzing Apparatus	Application No. 11/998,610 (Pending)
Fluid Sample Collecting and Analyzing Apparatus -- PCT	(Pending)

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks -

Name of Mark	Status
 <u>AMEDITECH, INC.</u>	(Pending)

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of September 22, 2009, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

ZYGARE, INC.

By: 

Name: David A. Teitel

Title: Chief Financial Officer and Treasurer

APPROVED
As To Form


Legal Department

[SIGNATURE PAGE TO ZYGARE COUNTERPART TO IP SECURITY AGREEMENT - SECOND LIEN]

TRADEMARK
REEL: 004166 FRAME: 0145

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Duly Authorized Signatory

[SIGNATURE PAGE TO ZYCARE COUNTERPART TO IP SECURITY AGREEMENT - SECOND LIEN]
LEGAL_US_E # 84972812

TRADEMARK
REEL: 004166 FRAME: 0146

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of ZyCare, Inc. ("ZyCare"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "Agreement"). The Supplemental Schedules (the "Schedules") are dated as of September 22, 2009 and give effect to, and contain data relating to ZyCare only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights -

None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents -

MBSS Docket No.	Title	Serial/App. No.	Filing Date	Patent No.	Patent Issued	Status
9025-1.CA	Patient-Operated Glucose Monitor and Diabetes Management System	537188	5/14/87	1,304,135	6/23/92	Expired 6/23/2009
9025-4	Patient-Operated Glucose Monitor and Diabetes Management System	06/864,506	5/19/86	4,731,726	3/15/88	Expired 5/19/2006
9025-6	Systems, Methods and Computer Program Products for Monitoring Diagnosing and Treating Medical Conditions of Remotely Located Patients	09/042,048	3/13/98	6,024,699	2/15/00	Expires 3/13/2018
9025-6.CT	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	09/470,774	12/23/99	6,589,169	7/8/03	Expires 3/13/2018
9025-6.AU	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	90926/99	12/21/98	754171	2/27/03	Expires 12/21/2018

9025-6.CA	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	2,322,563	12/21/98	2,322,563	9/9/08	Expires 12/21/2018
9025-6.CA2	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	2,630,207	12/21/98			Pending
9025-6.EP	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	98965467.8	12/21/98	1,062,615	5/2/03	Granted – Expires 12/21/2018- Validated in Germany, Spain, France, UK, Italy and Netherlands
9025-6.EP2	Systems, Methods and Computer Program Products for Monitoring, Diagnosing and Treating Medical Conditions of Remotely Located Patients	02001241.5	12/31/98			Pending – Published as EP I 197 907 A2 on 4/17/02
9025-7	Apparatus and Methods for Monitoring and Modifying Anti-Coagulation Therapy of	09/480,432	1/11/00	6,980,958	12/27/05	Expires 1/11/2020

	Remotely Located Patients					
9025-7CT	Apparatus and Methods for Monitoring and Modifying Anti-Coagulation Therapy of Remotely Located Patients	11/115,824	4/27/05			Pending (Appeal Filed w/Board of Appeals)
9025-7.CA	Apparatus and Methods for Monitoring and Modifying Anti-Coagulation Therapy of Remotely Located Patients	2,396,262	1/10/01			Pending Added claims from US continuation
9025-7.EP	Apparatus and Methods for Monitoring and Modifying Anti-Coagulation Therapy of Remotely Located Patients	01903011.3	7/4/02			Pending- Published as EP 1 248 555 on 10/16/02

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks -

- CoagCare®, "Direct to patient expert system"[™], "Supervised Self-Management"[™], and "Physician Supervised Patient Self-Management"[™],
- The Company holds the following domain names: www.coagcare.net, www.coagcare.com, www.zycare.net and www.zycare.com.
- The Company holds the following international registrations: www.coagcare.be, www.coagcare.ca, www.coagcare.co.uk, www.coagcare.de, www.coagcare.dk, www.coagcare.es, www.coagcare.eu, www.coagcare.ie, www.coagcare.it and www.coagcare.nl.


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of October 28, 2009, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Administrative Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]


FREE & CLEAR, INC.

By: 
Name: David A. Teitel
Title: Vice President, Finance and Treasurer

APPROVED
As To Form
Katie Danett
Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Duly Authorized Signatory

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Free & Clear, Inc. ("*Free & Clear*"), as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of October 28, 2009 and give effect to, and contain data relating to Free & Clear only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights -

None


SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Patents -

None.

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Trademarks --

- Person and circle design:  Registration date: 5/12/2009, Registration number: 3,620,590
- Accomplish: (Suspended). Application date: 4/11/2005, Application number: 78-606,397
- Free & Clear: Registration date: 4/18/2000, Registration number: 2,342,998
- Mind & Body: Registration date: 5/19/2009, Registration number: 3,624,086
- Quit Coach: Registration date: 11/13/2007, Registration number: 3,336,784
- Quit for Life: Registration date: 10/2/2007, Registration number: 3,303,981
- The 8 Essential Practices for a Healthy Mind & Body: Registration date: 6/9/2009, Registration number: 3,635,096
- The Healthy Behaviors Company: Application date: 4/1/2008, Application number: 77-436,833
- Viewpoint: Application date: 4/1/2008, Application number: 77-436,790
- Vital Signs: Application date: 5/23/2007, Application number: 77-436,790
- Web Coach: Registration date: 10/28/2008, Application number: 3,523,047
- Weight Talk: Registration date: 8/23/2005, Registration number: 2,987,213


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**


This counterpart, dated as of March 1, 2010, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the “Intellectual Property Security Agreement”; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]


LABORATORY SPECIALISTS OF AMERICA,
INC.
KROLL LABORATORY SPECIALISTS, INC.
SCIENTIFIC TESTING LABORATORIES, INC.

By: 
Name: Jay McNamara
Title: Assistant Secretary

APPROVED
As To Form

Legal Department

ACKNOWLEDGED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Ryan Guenin
Title: Duly Authorized Signatory

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Laboratory Specialists of America, Inc. and its subsidiaries (collectively "**KROLL**"), as Grantors to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "**Agreement**"). The Supplemental Schedules (the "**Schedules**") are dated as of March 1, 2010 and give effect to, and contain data relating to KROLL only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights –

Laboratory Specialists of America, Inc.

Company-developed software reporting tools:

KLsapp

KrollDatalink

SciTest.US

Labtest

Kroll Laboratory Specialists, Inc.

Company-developed software reporting tools:

KLsapp

KrollDatalink

SciTest.US

Labtest

Scientific Testing Laboratories, Inc.

Company-developed software reporting tools:

KLsapp

KrollDatalink

SciTest.US

Labtest

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents -

Laboratory Specialists of America, Inc.
None.

Kroll Laboratory Specialists, Inc.
None.

Scientific Testing Laboratories, Inc.
None.

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks –

Laboratory Specialists of America, Inc.
None.

Kroll Laboratory Specialists, Inc.
None.

Scientific Testing Laboratories, Inc.
Ownership of the service mark “Scientific Testing Laboratories, Inc.” –
Registration Number 1234063.